GCP
ACRS icon

GSA Capital Partners’s Aclaris Therapeutics ACRS Stock Holding History

GSA Capital Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-46,969
Closed -$67K – 1607
2025
Q2 		$67K Buy
46,969
+16,453
+54% +$22.3K ﹤0.01% 1642
2025
Q1 		$47K Buy
+30,516
New +$65.1K ﹤0.01% 1550
2024
Q4 		– Sell
-255,032
Closed -$293K – 1562
2024
Q3 		$293K Sell
255,032
-81,645
-24% -$100K 0.02% 1225
2024
Q2 		$370K Sell
336,677
-342,460
-50% -$402K 0.03% 1151
2024
Q1 		$842K Sell
679,137
-908,858
-57% -$1.08M 0.07% 554
2023
Q4 		$1.67M Buy
1,587,995
+1,550,026
+4,082% +$4.73M 0.14% 182
2023
Q3 		$260K Sell
37,969
-45,491
-55% -$389K 0.02% 1153
2023
Q2 		$865K Buy
83,460
+51,102
+158% +$462K 0.09% 397
2023
Q1 		$262K Buy
+32,358
New +$411K 0.03% 1107

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GSA Capital Partners's ACRS Position: Q3 2025 in Review

GSA Capital Partners sold out of Aclaris Therapeutics (ACRS) in Q3 2025, closing a stake of 46,969 shares — an estimated $67K sold.

GSA Capital Partners first reported a position in ACRS in Q1 2023 and held it in 9 quarters. The position peaked at $1.67M in Q4 2023. 103 funds tracked by Wall St. Rank hold ACRS as of Q3 2025.

  • GSA Capital Partners reported no remaining Aclaris Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 46,969 Aclaris Therapeutics shares in Q3 2025, an estimated $67K.
  • GSA Capital Partners first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 9 quarters.
  • GSA Capital Partners's Aclaris Therapeutics position peaked at $1.67M in Q4 2023.
  • 103 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.